Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + vinorelbine + trastuzumab + filgrastim
- Development stage
- Discontinued
- Lead developer
- University of Washington
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination therapy regimen, investigated by the University of Washington, is designed for the treatment of metastatic (Stage IV) breast cancer. It consists of two microtubule-targeting agents, paclitaxel and vinorelbine, which exert synergistic cytotoxic effects by stabilizing and inhibiting the polymerization of tubulin, respectively. For patients with HER2-overexpressing tumors, the regimen includes trastuzumab, a monoclonal antibody that targets the HER2 receptor to inhibit tumor cell proliferation. Filgrastim (granulocyte colony-stimulating factor or G-CSF) is integrated into the protocol as supportive care to stimulate neutrophil production and mitigate the risk of chemotherapy-induced neutropenia. This specific combination was evaluated in a Phase I/II clinical trial to determine optimal dosing, safety profiles, and therapeutic efficacy in prolonging survival for patients with advanced breast cancer.
- Other names
- Weekly paclitaxel and vinorelbine with G-CSF and trastuzumabNavelbine, Taxol, Herceptin and Neupogen regimen
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + vinorelbine + trastuzumab + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + vinorelbine + trastuzumab + filgrastim.